DOP2000000022A - Combinacion de inhibidores de mtp e inhibidores de hmg-coa reductasa y su uso en medicametos. - Google Patents

Combinacion de inhibidores de mtp e inhibidores de hmg-coa reductasa y su uso en medicametos.

Info

Publication number
DOP2000000022A
DOP2000000022A DO2000000022A DO2000000022A DOP2000000022A DO P2000000022 A DOP2000000022 A DO P2000000022A DO 2000000022 A DO2000000022 A DO 2000000022A DO 2000000022 A DO2000000022 A DO 2000000022A DO P2000000022 A DOP2000000022 A DO P2000000022A
Authority
DO
Dominican Republic
Prior art keywords
inhibitors
combination
hmg
medicines
mtp
Prior art date
Application number
DO2000000022A
Other languages
English (en)
Inventor
Rudi Grutzmann
Ulrich Muller
Hilma Bischoff
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of DOP2000000022A publication Critical patent/DOP2000000022A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La invención se refiere al use de una combinación de al menos un inhibidor de MTP seleccionado (componente A) y un inhibidor de HMg-CoA reductasa (componente B) para la lucha contra enfermedades del sistema cardiocirculatorio, a medicamentos que contienen esta combinación y a su obtención.
DO2000000022A 1999-06-25 2008-04-11 Combinacion de inhibidores de mtp e inhibidores de hmg-coa reductasa y su uso en medicametos. DOP2000000022A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19929065A DE19929065A1 (de) 1999-06-25 1999-06-25 Kombination von MTP-Inhibitoren und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln

Publications (1)

Publication Number Publication Date
DOP2000000022A true DOP2000000022A (es) 2008-08-15

Family

ID=7912459

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2000000022A DOP2000000022A (es) 1999-06-25 2008-04-11 Combinacion de inhibidores de mtp e inhibidores de hmg-coa reductasa y su uso en medicametos.

Country Status (12)

Country Link
EP (1) EP1196194A2 (es)
JP (1) JP2003503342A (es)
AR (1) AR028996A1 (es)
AU (1) AU5680900A (es)
CA (1) CA2376881A1 (es)
DE (1) DE19929065A1 (es)
DO (1) DOP2000000022A (es)
GT (1) GT200000099A (es)
PE (1) PE20010302A1 (es)
SV (1) SV2004000109A (es)
UY (1) UY26218A1 (es)
WO (1) WO2001000183A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10030375A1 (de) * 2000-06-21 2002-01-03 Bayer Ag Verwendung von MTP-Inhibitoren zur Senkung von ppTRL
KR20060053023A (ko) * 2002-02-28 2006-05-19 니뽄 다바코 산교 가부시키가이샤 에스테르 화합물 및 그 의약 용도
JP4832897B2 (ja) 2003-08-29 2011-12-07 日本たばこ産業株式会社 エステル誘導体及びその医薬用途
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
FR2884831B1 (fr) * 2005-04-22 2007-08-10 Merck Sante Soc Par Actions Si Methode de criblage de composes inhibiteurs de la mtp
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
US10905667B2 (en) 2018-07-24 2021-02-02 Bayer Pharma Aktiengesellschaft Orally administrable modified-release pharmaceutical dosage form
CN109053927A (zh) * 2018-08-08 2018-12-21 中山大学 一种含维生素b12基团的两亲性海藻酸钠衍生物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4435477A1 (de) * 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
DE19546918A1 (de) * 1995-12-15 1997-06-19 Bayer Ag Bicyclische Heterocyclen
DE19546919A1 (de) * 1995-12-15 1997-06-19 Bayer Ag N-Heterocyclisch substituierte Phenylessigsäure-Derivate
DE19615265A1 (de) * 1996-04-18 1997-12-04 Bayer Ag Neue Pyridazino-, Pyrimido-, Pyrazino- und Triazino-indole
SK65499A3 (en) * 1996-11-27 2001-05-10 Pfizer Apo b-secretion/mtp inhibitory amides
CA2286341A1 (en) * 1997-05-01 1998-11-12 John R. Ii Wetterau Mtp inhibitors and fat soluble vitamin therapeutic combinations to lower serum lipid levels

Also Published As

Publication number Publication date
UY26218A1 (es) 2001-01-31
DE19929065A1 (de) 2000-12-28
JP2003503342A (ja) 2003-01-28
PE20010302A1 (es) 2001-04-12
GT200000099A (es) 2001-12-13
AU5680900A (en) 2001-01-31
AR028996A1 (es) 2003-06-04
WO2001000183A2 (de) 2001-01-04
SV2004000109A (es) 2004-05-07
CA2376881A1 (en) 2001-01-04
EP1196194A2 (de) 2002-04-17
WO2001000183A3 (de) 2001-05-10

Similar Documents

Publication Publication Date Title
DOP2000000022A (es) Combinacion de inhibidores de mtp e inhibidores de hmg-coa reductasa y su uso en medicametos.
CL2017001847A1 (es) Una formulación sólida de dosificación farmacéutica
CY1120313T1 (el) Φαρμακευτικη συνθεση για δερματικη χρηση για να θεραπευεται ψωριαση που περιλαμβανει βιταμινη d και κορτικοστεοειδες
BRPI0413363A (pt) formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase
EE04990B1 (et) HMG reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid, nende kasutamine ja saamismeetod
CR7171A (es) Composiciones farmaceuticas de farmacos y polimeros acidos neutralizados
CY1107294T1 (el) Τοπικη συνθεση η οποια περιεχει τουλαχιστον μια βιταμινη d ή ενα αναλογο της βιταμινης d και τουλαχιστον ενα κορτικοστεροειδες
BR0317715A (pt) Composições e processos de uso de collajolie
PA8506101A1 (es) Uso de un compuesto acat para fabricar una composicion farmaceutica
BRPI0507654A (pt) composição farmacêutica compreendendo um derivado de benzodiazepina e um inibidor da proteìna de fusão de rsv
WO2007053641A3 (en) A-type procyanidins and inflammation
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
PA8577901A1 (es) Formulacion farmaceutica
AR019507A1 (es) Uso de los inhibidores de cyp2d6 en terapias de combinacion
PA8513601A1 (es) Composiciones farmaceuticas de inhibidores de la glucogenofosforilasa
BRPI0507652A (pt) composições farmacêuticas compreendendo um derivado de benzoidiazepina e um inibidor da proeìna de fusão de rsv
CY1110906T1 (el) Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης
BRPI0410555A (pt) preparação sólida
BR0211274A (pt) Combinação de um antagonista de receptor de aldosterona e um inibidor de hmg co-a redutase
CL2004000366A1 (es) USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
BR0002953A (pt) Composições e tratamento para complicações diabéticas
BR0110506A (pt) Uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose
CR6824A (es) Derivados de arilmetilamina para uso como inhibidores de triptasa
HUP0401854A2 (hu) COX-2 inhibitorokat és aszpirint tartalmazó kombinációk
AR030140A1 (es) Composiciones derivadas de la 2-piridinamina y metodos relacionados